Key facts
- This page summarizes James M. Daly's Form 4 filing for HALOZYME THERAPEUTICS, INC. (HALO).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 15 Aug 2023, 16:04.
James M. Daly - 11 Aug 2023 Form 4 Insider Report for HALOZYME THERAPEUTICS, INC. (HALO)
- Reporting relationship
- Director
- Issuer ticker
- HALO
- Reported as of
- 11 Aug 2023
- Net transaction value
- -$874,520
- SEC form
- 4
- Accepted by SEC
- 15 Aug 2023, 16:04:28 UTC
- Prior SEC filing
- 20 Jun 2023
- Next SEC filing
- 03 Apr 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ James Oehler, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
James M. Daly filed Form 4 for HALOZYME THERAPEUTICS, INC. (HALO) on 15 Aug 2023.
Change
- Previous filing in this sequence was filed on 20 Jun 2023.
- Current net transaction value: -$874,520.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
HALO
transaction
Common Stock
Sale
- Transaction value
- $437,110
- Shares
- -10,000
- Change %
- -25%
- Price
- $43.71
- Shares after
- 30,503
- Date
- 11 Aug 2023
- Ownership
- Direct
- Footnotes
- F1
HALO
transaction
Common Stock
Sale
- Transaction value
- $437,410
- Shares
- -10,000
- Change %
- -33%
- Price
- $43.74
- Shares after
- 20,503
- Date
- 14 Aug 2023
- Ownership
- Direct
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents a weighted average sales price per share. These shares were sold at prices ranging from $43.63 to $43.86. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Footnote F2
Represents a weighted average sales price per share. These shares were sold at prices ranging from $43.54 to $44.16. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.